Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Ministry of Health, Thailand | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
This is a community intervention effectiveness study in female school students in Thailand.
The study objectives are:
The study will investigate the effectiveness of a SD of HPV vaccine through the conduct of a regional effectiveness study in Thailand.
The study will be conducted in schools and district hospitals from the two selected provinces (Udon Thani and Buriram)
The study design includes 4 distinct and independent components:
1) vaccination, 2)baseline cross-sectional survey, 3,4)sequential cross-sectional surveys for impact assessments at Year 2 and Year 4 post vaccination.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cross-sectional baseline survey | No Intervention | This are will collect behavioral questionnaire and urine in Grade 10 high school and Year 1 vocational school and Grade 12 high school and Year 3 Vocational school female students | |
| Single Dose HPV vaccination | Active Comparator | Grade 8 female students from Udon Thani Province This arm will collect behavioral questionnaire and blood prior vaccination Intervention: Single Dose HPV Vaccination with CERVARIX®(Glaxo Smith Kline, GSK, Rixensart, Belgium) |
|
| Two-dose HPV vaccination | Active Comparator | Grade 8 female students from Buriram Province This arm will collect behavioral questionnaire and blood prior vaccination Intervention: Two-Dose HPV Vaccination with CERVARIX®(Glaxo Smith Kline, GSK, Rixensart, Belgium) |
|
| Cross-sectional survey at Year 2 | No Intervention | This arm will collect behavioral questionnaire, urine and blood in Grade 10 high school and Year 1 vocational school female students | |
| Cross-sectional survey at Year 4 | No Intervention | Cross-sectional survey at Year 4 post vaccination |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Bivalent HPV vaccine CERVARIX® | Biological | Bivalent HPV vaccine(Glaxo Smith Kline, GSK, Rixensart, Belgium) presented as a suspension for intramuscular injection containing purified viral L1 protein for HPV types 16 and 18. Each 0.5 mL dose of the bivalent vaccine contains 20μg of HPV-16 L1 protein and 20 μg of HPV-18 L1 protein adsorbed onto a proprietary adjuvant system containing 500 μg of aluminum hydroxide and 50 μg of 3-O-desacyl-4-monophosphoryl lipid A (AS04) |
| Measure | Description | Time Frame |
|---|---|---|
| HPV infection prevalence | HPV DNA PCR in urine | Baseline survey (unvaccinated students) during the first year of the study |
| HPV infection prevalence | HPV DNA PCR in urine | Year 2, two years post vaccination |
| HPV infection prevalence | HPV DNA PCR in urine | Year 4, four years post vaccination |
| Identification of HPV circulating strains | HPV genotyping on urine positive samples | Baseline survey (unvaccinated students) during the first year of the study |
| Identification of HPV circulating strains | HPV genotyping on urine positive samples | Year 2, two years post vaccination |
| Identification of HPV circulating strains | HPV genotyping on urine positive samples | Year 4, four years post vaccination |
| Measure | Description | Time Frame |
|---|---|---|
| HPV type-specific antibody response prior and post vaccination | Blood Sample | Prior vaccination and at Year 2 and Year 4 Post vaccination |
Not provided
Inclusion criteria
A. Grade 8 (Mathayom 2):
B. Baseline survey (Grade 10 / year 1, Grade 12 / year 3)
1. Female students with identification card Participant assent for questionnaire and urine collection
C. Year 2 post vaccination survey( Grade 10 / year 1) Year 4 post vaccination survey (Grade 12 / year 3)
Exclusion criteria
A. Grade 8 (Mathayom 2):
B. Baseline survey (Grade 10 / year 1, Grade 12 / year 3) 1. Any student who has a preexisting known medical condition or diagnosed psychological illness which in the opinion of the Principal Investigator or designee may be detrimental to her wellbeing
C. Year 2 post vaccination survey( Grade 10 / year 1) Year 4 post vaccination survey (Grade 12 / year 3)
1. Any student who has a preexisting known medical condition or diagnosed psychological illness which in the opinion of the Principal Investigator or designee may be detrimental to her wellbeing
Female students
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Suchada Jiamsiri, MD | Department of Disease Control, Thailand Ministry of Public Health, Bangkok | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ministry of Public Health | Bangkok | Chang Wat Nonthaburi | 11000 | Thailand |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D030361 | Papillomavirus Infections |
| ID | Term |
|---|---|
| D015229 | Sexually Transmitted Diseases, Viral |
| D012749 | Sexually Transmitted Diseases |
| D003141 | Communicable Diseases |
| D007239 | Infections |
Not provided
Not provided
Age range of subjects: 13 up to 18 years of age
Not provided
Not provided
Not provided
Not provided
|
| D004266 | DNA Virus Infections |
| D014777 | Virus Diseases |
| D014412 | Tumor Virus Infections |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |